Matthew R. Patterson Sells 25,000 Shares of Audentes Therapeutics Inc (BOLD) Stock
Audentes Therapeutics Inc (NASDAQ:BOLD) CEO Matthew R. Patterson sold 25,000 shares of Audentes Therapeutics stock in a transaction dated Monday, October 2nd. The stock was sold at an average price of $27.92, for a total value of $698,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
Shares of Audentes Therapeutics Inc (NASDAQ BOLD) traded up 0.04% during mid-day trading on Wednesday, reaching $27.36. 112,256 shares of the company’s stock traded hands. The company’s 50-day moving average price is $26.84 and its 200-day moving average price is $26.84. The stock’s market capitalization is $760.17 million. Audentes Therapeutics Inc has a 12-month low of $13.13 and a 12-month high of $33.43.
Audentes Therapeutics (NASDAQ:BOLD) last posted its quarterly earnings results on Thursday, August 10th. The biotechnology company reported ($0.87) earnings per share for the quarter, missing the consensus estimate of ($0.77) by ($0.10). Analysts anticipate that Audentes Therapeutics Inc will post ($3.50) earnings per share for the current year.
TRADEMARK VIOLATION NOTICE: “Matthew R. Patterson Sells 25,000 Shares of Audentes Therapeutics Inc (BOLD) Stock” was originally posted by American Banking News and is owned by of American Banking News. If you are viewing this article on another publication, it was illegally stolen and republished in violation of United States and international copyright and trademark legislation. The correct version of this article can be read at https://www.americanbankingnews.com/2017/10/04/matthew-r-patterson-sells-25000-shares-of-audentes-therapeutics-inc-bold-stock.html.
Institutional investors have recently bought and sold shares of the company. Sphera Funds Management LTD. purchased a new stake in shares of Audentes Therapeutics in the 2nd quarter valued at approximately $2,870,000. Spark Investment Management LLC purchased a new stake in shares of Audentes Therapeutics in the 1st quarter valued at approximately $472,000. Wells Fargo & Company MN grew its stake in shares of Audentes Therapeutics by 278.5% in the 1st quarter. Wells Fargo & Company MN now owns 7,747 shares of the biotechnology company’s stock valued at $132,000 after buying an additional 5,700 shares during the period. TD Asset Management Inc. grew its stake in shares of Audentes Therapeutics by 132.8% in the 1st quarter. TD Asset Management Inc. now owns 24,682 shares of the biotechnology company’s stock valued at $421,000 after buying an additional 14,082 shares during the period. Finally, Jennison Associates LLC grew its stake in shares of Audentes Therapeutics by 182.4% in the 2nd quarter. Jennison Associates LLC now owns 846,273 shares of the biotechnology company’s stock valued at $16,189,000 after buying an additional 546,617 shares during the period. 77.09% of the stock is owned by institutional investors and hedge funds.
Several research firms recently commented on BOLD. Bank of America Corporation reiterated a “buy” rating and issued a $33.00 price target (up previously from $23.00) on shares of Audentes Therapeutics in a research report on Friday, September 22nd. ValuEngine lowered Audentes Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, August 11th. Evercore ISI began coverage on Audentes Therapeutics in a research report on Wednesday, August 16th. They issued an “outperform” rating and a $23.00 price target for the company. Finally, Zacks Investment Research upgraded Audentes Therapeutics from a “hold” rating to a “buy” rating and set a $23.00 price target for the company in a research report on Monday, July 17th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $24.17.
Audentes Therapeutics Company Profile
Audentes Therapeutics, Inc is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT).
Receive News & Ratings for Audentes Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.